Paul Tudor Jones Syndax Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $29 Billion
- Q1 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 66,988 shares of SNDX stock, worth $836,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,988Holding current value
$836,010% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding SNDX
# of Institutions
239Shares Held
102MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$106 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$98.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$60.8 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$52.6 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$50 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $706M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...